Articles tagged with Target Proteins
Scientists have identified the specific protein targeted by snake venom that causes cells to detach and induce internal bleeding. Animals resistant to snake venom, such as opossums and camels, possess a variation of this protein that may provide protective benefits.
Charlotte Miton and Zach Schaefer have won the Protein Society's Year 2016 Best Paper award for their research on mutational epistasis and protein structure. Their study reveals that epistasis plays a major role in constraining evolutionary trajectories, with half of fixed mutations becoming positive at later rounds of evolution.
A new study has identified novel mechanisms by which T cells recognize emerging class of targets specifically increased on cancer cells. The study found that phosphorylation induces a major change in peptide structure and makes the critical receptor sensitive to discrimination between modified and non-modified peptides.
Researchers found that ubiquitin-interacting motifs in USP25 determine its preferential cleavage of Lys48-linked ubiquitin chains. The study reveals a unique mechanism for substrate specificity, which could have implications for understanding protein regulation and degradation.
A team of scientists used Met Office technology to study climate change and predicted the behavior of proteins within human cells. They discovered that tail-anchored membrane proteins are routed to specific organelles based on their chemical properties, such as charge and hydrophobicity.
A new study discovered a chemical compound that selectively stalls the production of specific proteins by targeting the ribosome. This approach offers a promising strategy for treating diseases, including cancer and cardiovascular disease.
Researchers have discovered a chemical compound that selectively stalls the ribosome, halting the production of specific proteins while leaving general protein production untouched. This discovery suggests a new approach to finding drugs that target undesired proteins before they are made.
Researchers have found a way to selectively degrade proteins that are difficult to target with drugs, using a small molecule approach that binds to neutralizing agents. The discovery provides a paradigm shift in targeting 'undruggable' proteins and offers new hope for cancer treatment and drug development.
A research team led by the University of Leicester identified a breakthrough in the cause of airway narrowing in severe asthma cases. The study found that an active form of key protein HMGB1 is increased and related to airway narrowing.
Researchers at Rockefeller University Press discovered that tumor suppressor protein RUNX1 can promote AML in some cases, particularly when combined with mutant FLT3. Targeting RUNX1 may be an effective treatment for certain AML patients, potentially offering a promising therapeutic strategy.
Researchers developed Nanobodies targeting RSV's fusion protein, neutralizing the virus and providing anti-viral activity in laboratory assays and animal models. The approach holds promise for developing a new therapy against RSV, a leading cause of lower respiratory tract infections in children.
A new study has developed an electrical immunosensor that can detect heart attacks within a minute using human serum. The system works by measuring the level of cardiac troponin I, a protein excreted by the heart muscle after a heart attack. This novel immunosensor holds considerable potential for use in biomedical diagnosis.
A team of scientists from Germany has identified a class of quinone-like substances with an epoxide functional group that can kill problematic Salmonella pathogens. The compounds work by interfering with the bacterial stress response system, making them a potential tool in the fight against multidrug resistance.
A recent UT Southwestern Medical Center study found that microRNA-515-5p affects placental development in ways that could contribute to preeclampsia. The research suggests miRNA-515-5p might be used to identify women at risk for the condition and potentially lead to a new treatment target.
Researchers at Nagoya University have identified a novel potential target of the type 2 diabetes drug metformin: the ion exchanger protein NHX-5. In nematode worms and fruit flies, metformin targets NHX-5 to disrupt autophagy and related subcellular processes.
Researchers at the University of Nottingham have discovered a protein that plays a role in the aging process, offering new hope for tackling age-related decline and neurodegenerative conditions. The protein, carbonic anhydrase, was found to be more active in middle-aged brains and reduced the life span of nematode worms.
The International Working Group on Antibody Validation has established five conceptual pillars for antibody validation, including genetic strategies, orthogonal methods, independent antibody approaches, expression of tagged proteins, and immunocapture followed by mass spectrometry. The proposal aims to provide a scientific foundation f...
Researchers at University of Oxford discover 'hitchhiking' effect of anti-HIV drugs on human metalloprotease, causing premature ageing. The mass spectrometry technique reveals unexpected binding of lopinavir, ritonavir and amprenavir to prelamin A protein.
Researchers at TSRI have developed a high-resolution view of how the ZMapp experimental therapy targets Ebola virus. The study revealed detailed images of the protein structures, providing new clues to improve the effectiveness of the antibodies in the treatment.
Researchers have identified a modified human protein essential for Ebola virus replication, offering new targets for therapeutic development.
Researchers have identified a protein called GlyRS that contributes to higher mortality in breast cancer patients by launching cancer growth. The study suggests targeting this protein could lead to the development of new anti-cancer therapies.
Scientists have developed a set of universal protein tags that enable accurate quantification of proteins using targeted proteomics techniques. The new tags, named PQS, are designed to work with selective reaction monitoring (SRM) and eliminate the need for labor-intensive assay development.
Scientists have made a breakthrough in visualizing proteins involved in cancer cell metabolism using cryo-EM. They were able to capture images of glutamate dehydrogenase at an atomic level, revealing new insights into potential drug targets. This discovery has the potential to revolutionize and accelerate the drug discovery process.
Researchers at Lund University have developed a method to target and destroy aggressive cancer cells using 'missiles' that can deliver lethal cell toxins. The study identified specific proteins on the surface of stressed cancer cells, which can be used as targets for delivering drugs into the cells, leaving healthy tissue unharmed.
PharmaMar showcases new compounds with unique mechanisms of action against solid and hematological tumors. Lurbinectedin attacks the microenvironment, Plitidepsin targets eEF1A2 protein, and PM184 disrupts blood vessels, cutting off nutrient and oxygen supply to tumor cells.
Researchers have developed a new experimental test that can detect signs of Lyme disease near the time of infection. The approach uses vesicle-like particles derived from the cell wall of the bacteria to provide a unique indicator of infection.
Researchers examine the efficacy profile of anti-prion antibodies, finding that toxicity depends on factors such as antibody dose and binding region. The study suggests that antibodies targeting the flexible tail region of PrP may be more promising candidates for immunotherapy.
A new optogenetic photosensitizer, FAP-TAPS, allows researchers to selectively manipulate cells using light. The technology has potential applications in studying cardiac regeneration and treating diseases such as cancer.
A team of scientists has discovered a mechanism by which tumor cells elevate levels of MDM4, a protein highly expressed in cancer cells. Targeting MDM4 abundance with antisense oligonucleotides (ASOs) impairs tumour growth and increases cell death, offering a promising clinically-compatible therapeutic target for various cancers.
Protein seekers can find genetic targets faster with obstacles in some cases, according to Rice University scientists. The study resolves conflicts between other research on protein interactions with DNA.
Researchers have identified a novel approach to targeting protein homeostasis in cancer, using p97 inhibitor CB-5083. Preclinical data show CB-5083 induces disease regression in acute myeloid leukemia and demonstrates antitumor activity in solid tumors.
A new vaccine has shown promise in reducing 'bad' LDL cholesterol levels in mice and macaques, suggesting potential as an alternative to statins. The vaccine targets the PCSK9 protein, which regulates cholesterol levels in the blood, offering a more powerful treatment with fewer side effects.
Researchers discovered how a mutant protein triggers nerve damage in CMT subtype CMT2D, a group of currently untreatable conditions. The study suggests future therapies may target this haywire protein to restore nerve function in patients with CMT.
A study using ^90Y-daclizumab, an anti-CD25 monoclonal antibody, achieved complete and partial responses in 50% of patients with relapsed Hodgkin's lymphoma. The treatment showed minor toxicity, but six patients developed myelodysplastic syndrome, limiting its use as a standalone therapy.
Researchers develop rapid and efficient method to target protein modification, enabling precise attachment of synthetic molecules. This technique has potential applications in antibody-drug conjugates for tumor therapy, outperforming existing methods.
New research highlights matricellular proteins as key targets for treating common ocular disorders. The special issue explores the function of these proteins and their role in inflammation and blood vessel formation in the eye.
Protein misfolding diseases are rising in incidence and seeing increasing financial and healthcare burden. Recent advances in understanding these disorders provide fresh ideas for their future therapy.
EPFL scientists develop a highly accurate detection system using firefly-inspired biotechnology, enabling quick diagnosis of cancer and protein interactions without requiring expensive equipment. The system utilizes a chemically-tweaked enzyme to produce light signals that can be seen with the naked eye.
Scientists have developed a new class of monoclonal antibodies that target misfolding proteins in neurodegenerative diseases. The antibodies successfully reverse damage to brain tissue in animals, suggesting a potential therapeutic agent for Alzheimer's and Parkinson's diseases.
A blood-borne molecule called beta-2 microglobulin increases with age and blocks brain cell regeneration, leading to cognitive decline. Administering the molecule to young mice reverses this effect, suggesting a potential therapeutic target for age-related cognitive diseases.
Researchers at ITbM have discovered new molecules that can change the circadian rhythm in mammals by targeting the clock protein CRY. The study found critical sites on the molecules for bioactivity, which were used to investigate the regulation of the clock protein in the body's timekeeping mechanism.
Researchers have developed a new tool to study TORC2, a protein critical for cell growth and cancer development. By understanding its structure and function, scientists can identify potential inhibitors of this complex, which could lead to the development of new anti-cancer agents.
Dana-Farber Cancer Institute scientists have developed a new, potent form of targeted cancer therapy using tumor cells' own protein-chopping machinery. The approach causes cancer cells to die quickly, potentially preventing resistance to conventional targeted therapies.
Researchers from Universities of Hamburg and Aarhus decode molecular structure of two promising drug candidates from Spiegelmers for the first time. The results provide a deeper understanding of the mode of action of these substances that have already entered clinical trials.
Researchers have identified a protective mechanism for tail-anchored proteins, which are crucial for various cellular functions. The study reveals a dimeric structure of the transport molecule Get3 that shields these proteins from harmful aggregation and guides them to the correct membrane location.
The discovery of Protein Targeting to Starch (PTST) reveals the crucial role of a molecule in transporting Granular Bound Starch Synthase (GBSS) to starch granules, necessary for normal amylose synthesis. The research found that PTST is essential for GBSS stability and function.
Scientists developed an antiviral compound targeting VP24, a key protein in the Ebola virus, which protected 75% of infected monkeys. The compound, AVI-7537, was found to be safe and well-tolerated, offering hope for developing effective therapies against the deadly disease.
Researchers at Brunel University London found proteins that disguise nanoparticles, allowing them to target cancer cells without causing inflammation. This discovery has potential for treating inflammatory diseases like Parkinson's and Alzheimer's, and glioblastoma brain tumors.
Researchers at Indiana University identified two proteins, FAK and PAK1, as crucial for the development of acute myeloid leukemia. They also found that targeting these proteins can block the disease's progression.
Researchers have identified a novel way to target newly manufactured proteins to the correct location in cells, utilizing a previously unknown compartment called an acidocalcisome. This discovery has implications for understanding protein function and regulation.
Researchers developed an optical method called iSCAT to detect individual proteins, such as those in cancers, using scattered light shadows. The method promises more sensitive diagnoses and sheds light on fundamental biochemical processes.
Researchers have uncovered how bacteria control their growth and division by destroying key proteins through regulated protein degradation, a critical process for bacterial virulence. Understanding this mechanism may lead to the discovery of new antibiotics targeting pathways that allow bacteria to overcome stressful conditions.
Scientists have discovered that ancient protein-building enzymes have acquired new functions in humans, including producing variants with diverse biological activities. These variants are produced only in specific cell types and appear during certain stages of development, highlighting a previously unrecognized layer of biology.
Researchers used mass spectrometry to study CMV's dynamics in infected cells, identifying ways the virus evades the immune system and targeting cell surface proteins. The discovery offers new therapeutic targets and potential treatments for CMV-related diseases.
Researchers found exercise training significantly reduces HSP90 overexpression in PD rats, suggesting a potential therapeutic target for skeletal muscle abnormalities. This study supports the use of HSP90 inhibitors as a new treatment option for PD-related muscle issues.
A protein called Kindlin-3 has been identified as a key player in both the formation and spread of breast cancer. The discovery suggests that targeting Kindlin-3 could lead to an entirely new class of breast cancer drugs, potentially slowing or reversing disease progression.
Researchers at Cornell University have developed a new type of antibody, called a ubiquibody, which can target specific proteins for destruction. This technology could provide a powerful way to fine-tune research on protein deletion or reduction, and may also prove useful for future drug therapies.
Researchers have identified specific behavior of PP1 by analyzing binding motifs with regulatory proteins. This discovery allows them to predict interactions with a significant number of proteins without resolving their structure.
Researchers at The Scripps Research Institute found a protein, Protein M, that attaches to antibodies and prevents them from binding to their target, helping bacteria evade the immune response. This discovery could lead to new antibacterial therapies and tools for research and drug development.
Researchers at Stanford University developed a microarray to identify cytokines, chemokines, and other proteins targeted by SLE patients' autoantibodies. They found that patients with high levels of autoantibodies against B cell activating factor (BAFF) experienced more severe symptoms.